STAAR Surgical’s first quarter performance was met with a strong positive market reaction, reflecting the company’s progress in resolving prior operational disruptions and inventory challenges. Management credited this turnaround to robust sales in China, early momentum from the EVO+ lens launch, and a return to normalized distributor inventory levels. Interim Co-CEO Warren Foust emphasized, “We have now largely moved past many of the challenges that we faced in 2025...those issues are behind us.” Improved execution across major markets, particularly in the United States, and disciplined spending contributed to the company’s return to profitability.

Is now the time to buy STAA? Find out in our full research report (it’s free for active Edge members).

While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.

Our Top 5 Analyst Questions From STAAR Surgical’s Q1 Earnings Call

• John Young (Canaccord Genuity) asked how Q1 sets a baseline for the rest of the year and if seasonality in China can be counted on. Interim Co-CEO Warren Foust stated that while Q1 was strong, historical seasonality may not repeat due to lingering macro and geopolitical factors.

• Thomas Stephan (Stifel) questioned China competition, especially from iBright, and its market impact. Foust responded that iBright currently poses little threat, as its adoption is limited and does not offer toric lenses.

• Gursimran Kaur (Wells Fargo) inquired about inventory normalization in China and EVO+’s revenue contribution. Foust and Andrews confirmed inventory is aligned with demand and that EVO+ is seeing premium adoption but declined to disclose exact figures.

• Ryan Zimmerman (BTIG) pressed on consignment inventory and the potential for 1Q to 2Q sales step-up. Andrews reiterated that Q1 was “clean” but stopped short of predicting a repeat, citing the need for further stability before providing guidance.

• Mason Carrico (Stephens) asked about ex-China growth and the impact of the expanded U.S. age indication. Foust said ex-China markets showed mid-single-digit growth, with the U.S. showing promise, and estimated 8 million additional U.S. candidates from the new approval.

Catalysts in Upcoming Quarters

In coming quarters, StockStory analysts will be closely monitoring (1) the pace and sustainability of EVO+ adoption in China and whether normalized inventory levels persist, (2) execution on scaling Swiss manufacturing to meet global demand and optimize margins, and (3) evidence of continued growth in the U.S. market following the recent regulatory expansion. Progress on ERP integration and efficiency improvements will also be important markers of operational scalability.

STAAR Surgical currently trades at $32.58, up from $29.40 just before the earnings. Is there an opportunity in the stock?Find out in our full research report (it’s free).

The Best Stocks for High-Quality Investors

ALSO WORTH WATCHING: Top 5 Momentum Stocks. The best time to own a great stock is when the market is finally noticing it. These aren't just high-quality businesses. Something is happening with them right now. Elite fundamentals meeting near-term momentum - both boxes checked at the same time.

Find out which stocks our AI platform is flagging this week. See this week's Strong Momentum stocks - FREE. Get Our Strong Momentum Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today.